GLP-1 Market
LLY $1115.70 ▼ -0.7% NVO $43.07 ▼ -2.1% PFE $27.72 ▲ +0.3% VKTX $31.98 ▼ -0.5% KLRA $13.94 ▼ -6.5% GPCR $38.66 ▼ -2.3% RHHBY $52.82 ▼ -0.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Mibavademab

Company
Regeneron Pharmaceuticals
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
3 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

3 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 12, 2026

Find a Clinical Trial Near Me

See recruiting studies for Mibavademab and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07220772

    A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults

    Not yet reported Regeneron Pharmaceuticals 4 participants Est. completion 2028-04-21 1 site Stand-alone
    Other conditions: Monogenic Obesity
    View official trial listing →
  • Recruiting NCT NCT07220785

    Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy

    Not yet reported Regeneron Pharmaceuticals 28 participants Est. completion 2028-09-08 7 sites Stand-alone
    Other conditions: Generalized Lipodystrophy
    View official trial listing →
  • Recruiting NCT NCT07235917

    A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea

    Not yet reported Regeneron Pharmaceuticals 34 participants Est. completion 2027-12-08 10 sites Stand-alone
    Other conditions: Functional Hypothalamic Amenorrhea (FHA)
    View official trial listing →
  • Completed NCT NCT03530514

    A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers

    Not yet reported Regeneron Pharmaceuticals 113 participants Est. completion 2020-01-27 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT04159415

    Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

    Not yet reported Regeneron Pharmaceuticals 16 participants Est. completion 2024-09-24 8 sites Stand-alone
    Other conditions: Generalized Lipodystrophy
    View official trial listing →
  • Available NCT NCT04710056

    Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling

    Regeneron Pharmaceuticals
    Other conditions: Lipodystrophy, Generalized Lipodystrophy (GLD), Monogenic Obesity (MOB)
    View official trial listing →
  • Terminated NCT NCT05088460

    A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)

    Not yet reported Regeneron Pharmaceuticals 20 participants Est. completion 2024-04-18 8 sites Stand-alone
    Other conditions: Familial Partial Lipodystrophy, Metabolic Abnormalities
    View official trial listing →
  • Completed NCT NCT06373146

    A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

    Not yet reported Eli Lilly and Company 392 participants Est. completion 2026-04-02 17 sites Added to GLP-1
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT06548100

    A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

    Not yet reported Regeneron Pharmaceuticals 9 participants Est. completion 2026-07-09 2 sites Stand-alone
    Other conditions: Generalized Lipodystrophy
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Mibavademab, REGN4461

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.